Pathios Therapeutics is an Oxford, UK-based biotech focused on developing small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 for cancer immunotherapy. The company aims to counteract GPR65-mediated immunosuppressive polarization of immune cells, including tumor-associated macrophages, driven by the acidic tumor microenvironment common to many cancers. GPR65 has been genetically associated with a range of immunologically mediated diseases, supporting the target rationale. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. It is led by co-founder and executive chair Tom McCarthy, Ph.D., and CEO Stuart Hughes, Ph.D. The company intends to use recent financing to continue development of its GPR65 inhibition approach. Pathios Therapeutics Limited, launched in 2017 by Tom McCarthy, is an Oxford, England, UK–based drug discovery and development company focused on modulators of GPR65. The company targets GPR65 signalling in both adaptive and innate immune cells to counteract the effects of abnormally acidic pathological environments. Pathios is developing therapies aimed at autoimmune diseases and cancer. It raised US$8.8M in a Series A financing to advance its development programs. Backers included Canaan and Australia’s Medical Research Commercialisation Fund managed by Brandon Capital. The company also announced the appointment of Stuart Hughes as Chief Executive Officer and Director; Hughes was formerly Senior Director and Head of Pharmacology at Vertex (Europe) and has experience leading translational drug development programs.

Total raised

$34M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2024